TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genprex ( (GNPX) ) has provided an update.
On November 18, 2025, Genprex announced that it has been granted a U.S. patent for its lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, securing exclusivity through 2037. This patent supports the Acclaim-3 clinical trial, which is evaluating the combination as a maintenance therapy for extensive stage small cell lung cancer. The trial, supported by FDA Fast Track and Orphan Drug Designations, aims to determine the progression-free survival rate and is expected to complete interim analysis in the first half of 2026.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for cancer and diabetes. Its primary product is Reqorsa® Gene Therapy, which is being tested in combination with PD-L1 antibodies for cancer treatment.
Average Trading Volume: 760,843
Technical Sentiment Signal: Sell
Current Market Cap: $8.62M
Learn more about GNPX stock on TipRanks’ Stock Analysis page.